Loading...
01/10 16:00
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several negative aspects: declining revenue and gross profit, reduced margins, significant M&A expenses, and wholesale revenue decline. The Q&A session lacked clarity on MusclePharm's performance and margins, adding uncertainty. Despite some positive aspects like online sales growth and product launches, the weak guidance, declining margins, and absence of a share buyback program suggest a negative market reaction.
Total Revenue $15.9 million, a decline of 4% year-over-year due to decreased sales across various channels.
Gross Profit Declined 6% year-over-year, with gross margin decreasing from 44% to 43.1% due to lower sales and increased costs.
Contribution $5.8 million, a decline of 4% year-over-year, attributed to reduced gross profit.
Net Income $2 million, down from $2.2 million year-over-year, impacted by significant M&A-related expenses.
Basic Earnings Per Share $0.22, down from $0.23 year-over-year, reflecting the decline in net income.
Diluted Earnings Per Share $0.20, down from $0.21 year-over-year, also impacted by net income decline.
Adjusted EBITDA $3.4 million, a 6% decrease year-over-year, primarily due to lower revenue and increased expenses.
Legacy FitLife Revenue $7.3 million, a 5% increase year-over-year, driven by an 11% increase in online sales.
MRC Revenue $6.7 million, down 11% year-over-year, due to a decline in sales from key brands.
MusclePharm Revenue Declined 6% year-over-year, with wholesale revenue down 41% and online revenue up 33%.
MusclePharm Gross Margin Declined from 40% to 30.1% year-over-year, impacted by increased promotional investments.
Net Debt $6 million, equivalent to approximately 0.4x adjusted EBITDA of $13.9 million for the past 12 months.
Active Subscribers Approximately 104,000, accounting for about 30% of online revenue.
Market Capitalization Around $140 million as of April 30, 2025, with potential inclusion in the Russell 2000 Index.
Market Capitalization: As of April 30, 2025, FitLife's market capitalization was around $140 million, with expectations of being added to the Russell 2000 Index.
Active Subscribers: FitLife has approximately 104,000 active subscribers, accounting for 30% of online revenue.
Inventory Levels: Inventory is at an all-time high due to intentional increases at pre-tariff prices.
M&A Activity: The company is actively pursuing one or more transactions, resulting in elevated M&A-related expenses.
Promotional Investments: Increased marketing allowances and promotional support for MusclePharm products are ongoing.
Revenue Decline: Total revenue declined 4% year-over-year to $15.9 million, indicating potential challenges in maintaining sales growth.
Gross Margin Decline: Gross margin decreased from 44% to 43.1%, suggesting increased costs or pricing pressures affecting profitability.
M&A-Related Expenses: Significant M&A-related expenses were incurred, with caution advised as increased spending may not lead to successful transactions.
Tariff Environment: Uncertainty in the tariff environment, particularly concerning ingredients from China, poses a risk to cost structures and supply chain.
Wholesale Revenue Decline: Wholesale revenue for MusclePharm declined 41%, indicating challenges in maintaining relationships with key wholesale customers.
Inventory Levels: High inventory levels due to pre-tariff purchases may lead to cash flow issues if not managed properly.
Market Capitalization Risks: Potential inclusion in the Russell 2000 Index is uncertain and outside the company's control, which could impact stock performance.
Customer Subscription Variability: Active subscriptions account for 30% of online revenue, with fluctuations in this metric posing risks to revenue stability.
M&A Activity: The company has increased spending in pursuit of one or more possible transactions, although it cautions that increased spend may not always result in a successful transaction.
Inventory Management: The company has increased finished goods and raw materials inventories at pre-tariff prices, resulting in an all-time high inventory level as of the end of Q1 2025.
Active Subscriptions: As of a week ago, FitLife had approximately 104,000 active subscribers, accounting for about 30% of the company's online revenue.
Russell 2000 Index Inclusion: FitLife is likely to be added to the Russell 2000 Index based on market capitalization analysis, which could serve as a positive catalyst for the stock.
Revenue and EBITDA Outlook: Total company revenue and adjusted EBITDA were up year-over-year in April 2025, despite declines in the Dr. Tobias brand.
Forward-Looking Guidance: The company will not be providing formal forward-looking guidance, but April's performance is noted as potentially encouraging.
Share Buyback Program: None
The earnings call reveals several negative factors: declining margins, increased tax expenses, and unresolved issues with Dr. Tobias on Amazon. Although MusclePharm shows growth, it's primarily from existing customers. Rising protein costs and potential further margin declines are concerning. Despite optimistic guidance for Irwin's online sales, the lack of clarity on subscriber trends and management's avoidance of detailed responses contribute to a negative sentiment. Without a market cap, the negative impact is assumed to be moderate.
The earnings call summary presents a mixed picture. Positive aspects include potential revenue synergies from the FitLife-Irwin merger and the likelihood of inclusion in the Russell 2000 Index. However, the lack of forward-looking guidance and challenges with Dr. Tobias brand balance these positives. The Q&A section reinforces this neutral stance with uncertainties regarding Irwin's revenue growth and the integration process. Overall, the absence of clear guidance and the focus on addressing brand challenges suggest a cautious market reaction, resulting in a neutral stock price prediction.
The earnings call highlights several negative aspects: declining revenue and gross profit, reduced margins, significant M&A expenses, and wholesale revenue decline. The Q&A session lacked clarity on MusclePharm's performance and margins, adding uncertainty. Despite some positive aspects like online sales growth and product launches, the weak guidance, declining margins, and absence of a share buyback program suggest a negative market reaction.
The earnings call summary shows strong financial performance with increased gross margin and contribution, and significant revenue growth. Despite a decline in online revenue, wholesale revenue surged, and adjusted EBITDA rose 39% YoY. The Q&A highlighted optimism in rebranding and new products, though management was vague on some details. The lack of new partnerships or guidance changes, and no severe risks identified, points to a positive sentiment. However, uncertainties in promotional expenses and GNC relations slightly temper the outlook, resulting in a positive stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
